DE69224590D1 - Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine - Google Patents

Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine

Info

Publication number
DE69224590D1
DE69224590D1 DE69224590T DE69224590T DE69224590D1 DE 69224590 D1 DE69224590 D1 DE 69224590D1 DE 69224590 T DE69224590 T DE 69224590T DE 69224590 T DE69224590 T DE 69224590T DE 69224590 D1 DE69224590 D1 DE 69224590D1
Authority
DE
Germany
Prior art keywords
hepatitis
stem
havs
relates
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69224590T
Other languages
English (en)
Other versions
DE69224590T2 (de
Inventor
Reinhard Glueck
Stefan Brantschen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Schweiz Serum und Impfinstitut Bern
Schweiz Serum und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum und Impfinstitut Bern, Schweiz Serum und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten filed Critical Schweiz Serum und Impfinstitut Bern
Application granted granted Critical
Publication of DE69224590D1 publication Critical patent/DE69224590D1/de
Publication of DE69224590T2 publication Critical patent/DE69224590T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69224590T 1991-05-08 1992-05-08 Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine Expired - Lifetime DE69224590T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91107526 1991-05-08
PCT/EP1992/001013 WO1992019268A1 (en) 1991-05-08 1992-05-08 New hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines

Publications (2)

Publication Number Publication Date
DE69224590D1 true DE69224590D1 (de) 1998-04-09
DE69224590T2 DE69224590T2 (de) 1998-10-15

Family

ID=8206711

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69224590T Expired - Lifetime DE69224590T2 (de) 1991-05-08 1992-05-08 Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine
DE199292910019T Pending DE542949T1 (de) 1991-05-08 1992-05-08 Hepatitis a virusstamm, verfahren zur isolierung eines hepatitis a virusstammes und vakzine hepatitis a.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE199292910019T Pending DE542949T1 (de) 1991-05-08 1992-05-08 Hepatitis a virusstamm, verfahren zur isolierung eines hepatitis a virusstammes und vakzine hepatitis a.

Country Status (10)

Country Link
EP (1) EP0542949B1 (de)
JP (1) JP3527238B2 (de)
AT (1) ATE163548T1 (de)
AU (1) AU662528B2 (de)
CA (1) CA2086832C (de)
DE (2) DE69224590T2 (de)
DK (1) DK0542949T3 (de)
ES (1) ES2056780T3 (de)
GR (2) GR930300089T1 (de)
WO (1) WO1992019268A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3523646B2 (ja) 1992-09-18 2004-04-26 スミスクライン・ビーチヤム・バイオロジカルズ・エス・エイ Ａ型肝炎ワクチン
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same
PL1802746T3 (pl) 2004-10-27 2011-10-31 Crucell Switzerland Ag Cząstki wirosomu zawierające antygeny wirusa grypy i wirusa zapalenia wątroby typu B
CN116514965B (zh) * 2023-06-15 2023-11-10 上海精翰生物科技有限公司 甲型肝炎病毒抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2398504A1 (fr) * 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
CA1164799A (en) * 1979-09-04 1984-04-03 Paula A. Giesa Cell culture of hepatitis a virus

Also Published As

Publication number Publication date
CA2086832C (en) 2007-05-01
DE69224590T2 (de) 1998-10-15
ATE163548T1 (de) 1998-03-15
WO1992019268A1 (en) 1992-11-12
GR3026612T3 (en) 1998-07-31
GR930300089T1 (en) 1993-09-30
DE542949T1 (de) 1993-09-02
JPH06500238A (ja) 1994-01-13
EP0542949B1 (de) 1998-03-04
ES2056780T1 (es) 1994-10-16
CA2086832A1 (en) 1992-11-09
JP3527238B2 (ja) 2004-05-17
ES2056780T3 (es) 1998-08-16
DK0542949T3 (da) 1998-12-07
AU1743692A (en) 1992-12-21
EP0542949A1 (de) 1993-05-26
AU662528B2 (en) 1995-09-07

Similar Documents

Publication Publication Date Title
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
YU9097A (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
EP0571613A4 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
PT97159A (pt) Processo para a preparacao de uma proteina do antigenio de superficie da hepatite b ou de um seu fragmento e processo para a preparacao de uma vacina
ATE125157T1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
NO870412L (no) Peptider.
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
FI942369A0 (fi) Hepatitis-C-virustesti
ATE127024T1 (de) Immunogene komplexe, insbesondere iscoms.
KR930702387A (ko) Hcv 펩티드-항원 및 c형 간염 바이러스(hcv)의 검사방법
Weiland et al. Development of monoclonal neutralizing antibodies against bovine viral diarrhea virus after pretreatment of mice with normal bovine cells and cyclophosphamide
ATE162550T1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
DE69224590D1 (de) Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine
WO1999013907A3 (en) Methods to improve immunogenicity of antigens and specificity of antibodies
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
EP0967223A3 (de) Hepatitis C Virus Peptidantigene und Verfahren zur Bestimung von Hepatitis C Virus (HCV)
ATE518879T1 (de) Verfahren zur herstellung eines partiellen orf2 proteins des hepatitis e virus
ATE178096T1 (de) Monoklonale antikörper gegen den hepatitis c- virus und verfahren diese zu benutzen
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
ES2126598T3 (es) Anticuerpos monoclonales que se fijan sobre las proteinas ns5 supuestas del virus de la hepatitis c, y procedimientos de utilizacion de estos anticuerpos.
KR910005887A (ko) 면역원성 물질의 고-보존된 아미노산 서열에 대한 항체, 이의 항체의 제조 방법 및 면역 감정에서의 이의 용도
Sarma et al. Production and characterization of monoclonal antibodies against a local isolate of classical swine fever virus
Osterhaus et al. Production of monoclonal antibodies against poliomyelitis and rabies viruses
TW377295B (en) Stnthetic peptides specific for detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 542949

Country of ref document: EP